Press release
Investigation announced for Investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) over potential Wrongdoing
An investigation on behalf of investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares over potential wrongdoing.
Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and currently hold any of those NASDAQ: REGN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Regeneron Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Tarrytown, NY based Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
In 2020, The U.S. Attorney's office filed suit against Regeneron Pharmaceuticals, Inc.. The complaint alleged that Regeneron Pharmaceuticals, Inc. funneled tens of millions of dollars in kickbacks through a third-party foundation to ensure that few Medicare patients paid a co-pay on Eylea and that physicians who prescribed and purchased the drug did not have to collect Medicare co-pays from their patients. Regeneron Pharmaceuticals, Inc. allegedly paid these substantial sums only after confirming that the foundation needed the money to cover co-pays only for Eylea and not for competing drugs. The company's payments would generate a handsome return on investment, or 'ROI,' in the form of Medicare payments for Eylea. Furthermore, senior company executives allegedly took extensive measures to cover up the scheme.
Those who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) over potential Wrongdoing here
News-ID: 2633969 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Regeneron
Myopic macular degeneration Market: Epidemiology, Therapies, Companies, DelveIns …
Myopic macular degeneration therapies, such as EYLEA (aflibercept), VABYSMO (faricimab), and others, are expected to boost the Myopic macular degeneration Market in the upcoming years.
DelveInsight has launched a new report on "Myopic macular degeneration - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Myopic macular degeneration, historical and forecasted epidemiology as well as the Myopic macular degeneration market trends in the United States, EU5 (Germany,…
Multiple Myeloma Market on Track for Major Expansion by 2034, According to Delve …
The Key Multiple Myeloma Companies in the market incude - Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others.
The Multiple Myeloma market is expected to surge due to the disease's increasing…
Filariasis Market Outlook Report 2032 | AstraZeneca, GlaxoSmithKline, Sanofi, Re …
DelveInsight's "Filariasis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Filariasis, historical and forecasted epidemiology, as well as the Filariasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Filariasis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Filariasis market size from 2019 to 2032, segmented…
Oral Antiviral Medicine Market Thriving at a Tremendous Growth | MSD, GSK, Regen …
Global Oral Antiviral Medicine Market Growth 2022-2028 , Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider Oral Antiviral Medicine market, and…
Investigation announced for Investors in shares of Regeneron Pharmaceuticals, In …
An investigation was announced concerning potential securities laws violations by Regeneron Pharmaceuticals, Inc. in connection with certain financial statements.
Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Regeneron Pharmaceuticals, Inc. regarding its business, its prospects and its operations were…
Antibody Cocktails Market to Witness Huge Growth by 2026 | Roche, Regeneron, Agi …
Global Antibody Cocktails Market Research Report 2016-2026 is latest research study released by HTF MI evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Global Antibody Cocktails Market. Some of the key players profiled in the study are Roche Holding AG, Regeneron Pharmaceuticals &…
